Health Trials

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

ConditionGlaucoma
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorGlaukos Corporation

About this trial

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Eligibility criteria

Qualifiers

Diagnosis of open-angle glaucoma or ocular hypertension in the study eye

Disqualifiers

Prior incisional glaucoma surgery in the study eye

Prior argon laser trabeculoplasty (ALT) in the study eye

Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Trial design

Treatments tested in this trial

  • Gen 2 Travoprost Intracameral Implant
  • Timolol eye drops 0.5%
  • Sham Procedure
  • Placebo eye drops

Treatment groups

610 Participants
are divided into 9 treatment groups

9

Treatment groups

See each treatment group below.

Sponsors and collaborators

Glaukos Corporation

Lead sponsor

Source ClinicalTrials.gov